Jason Lee, PhD

Senior Scientist at Conception

Jason Lee, PhD has extensive experience in the field of cell differentiation and stem cell research. Jason currently holds roles as a Cell Differentiation Scientist and Senior Scientist at Ovid Research. Prior to their current positions, they worked as a Postdoctoral Research Fellow at The University of Texas at Austin, where they led research on the therapeutic use of stem cells for vascular recovery and made significant contributions to the field. Jason designed and built a high throughput device for applying mechanical forces to stem cell cultures and improved upon an implantable device for regenerating vascular and neural functions in impaired limbs. During their time at the university, they initiated four independent Ph.D. student projects, presented at prestigious conferences, and published multiple manuscripts and a book chapter. Jason also trained colleagues as the most experienced member of the lab. Before their postdoctoral research, Jason served as a Graduate Research Assistant at The University of Texas at Austin. Overall, Jason has a strong background in stem cell research and has made valuable contributions to the field through their work at various research institutions.

Jason Lee, PhD, obtained their Bachelor of Science (BS) degree in Bioengineering and Biomedical Engineering from Cornell University in 2011. Jason then pursued a Master of Engineering (MEng) degree in Biomedical/Medical Engineering from Cornell University, graduating in 2012. After that, they enrolled in The University of Texas at Austin, where they completed their Doctor of Philosophy (Ph.D.) in Biomedical/Medical Engineering in 2016. In 2018, Jason also obtained a certification as a Certified LabVIEW Associate Developer from the National Instruments.

Location

Berkeley, United States

Links


Org chart

No direct reports

Teams


Offices


Conception

Conception is a company developing the technology to turn skin cells into viable human eggs.This technology will give women the opportunity to have children well into their forties and fifties, eliminate barriers for couples suffering from infertility, and potentially allow male-male couples to have biological children.Long term, thistechnology could be a critical platform allowing for widespread genetic screening of embryos. If proven safe, it could even enable for genetic editing to eliminate and reduce the risk of devastating diseases for future generations – such as Alzheimer’s, heart disease and many different types of cancers.This could become one of the most important technologies ever created.The company was founded in 2018 and is headquartered in Berkeley, California.


Employees

11-50

Links